StoxIpca Laboratories vs Glaxosmithkline Pharmaceuticals: share price & financials comparison
NSE: IPCALAB vs GLAXO · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Ipca Laboratories vs Glaxosmithkline Pharmaceuticals at a glance
Ipca Laboratories (IPCALAB) has a market capitalisation of ₹49,263 Cr, against ₹42,773 Cr for Glaxosmithkline Pharmaceuticals (GLAXO). Over the past year Ipca Laboratories has returned +50.5%, compared with -4.5% for Glaxosmithkline Pharmaceuticals. On valuation, Ipca Laboratories trades at a lower P/E of 35.1 versus 83.0. Glaxosmithkline Pharmaceuticals earns a higher return on equity (27.4% vs 16.2%). Ipca Laboratories comes out ahead on size, valuation, momentum and technicals. Glaxosmithkline Pharmaceuticals comes out ahead on profitability. Across the scored metrics below, Ipca Laboratories leads on 12 and Glaxosmithkline Pharmaceuticals on 4. On StoxGud's 10-point checklist, Ipca Laboratories scores 9/10 and Glaxosmithkline Pharmaceuticals scores 7/10.
| Metric | Ipca Laboratories | Glaxosmithkline Pharmaceuticals |
|---|---|---|
| Size | ||
| Market cap | ₹49,263 Cr | ₹42,773 Cr |
| Revenue (latest FY) | ₹9,646 Cr | ₹3,822 Cr |
| Net profit (latest FY) | ₹1,141 Cr | ₹1,036 Cr |
| Valuation | ||
| P/E | 35.1 | 83.0 |
| P/B | 5.68 | 22.74 |
| Dividend yield | 0.11% | 1.67% |
| Profitability | ||
| Return on equity | 16.2% | 27.4% |
| Net profit margin | 13.4% | 12.4% |
| Operating margin | 22.5% | 34.1% |
| Growth | ||
| Revenue growth (YoY) | +13.8% | +20.8% |
| Net profit growth (YoY) | +32.8% | — |
| Revenue CAGR (multi-year) | +12.2% | +2.9% |
| Financial health | ||
| Debt to equity | 0.07 | 0.00 |
| Momentum | ||
| 1-month return | +0.2% | -4.1% |
| 1-year return | +50.5% | -4.5% |
| 3-year CAGR | +25.4% | +20.8% |
| 5-year CAGR | +12.9% | +8.6% |
| 10-year CAGR | +21.0% | +6.1% |
| Distance from 52W high | -3.4% | -18.7% |
| Technicals | ||
| RSI (14) | 65 | 46 |
| Price vs 200-day avg | +15.1% | +0.3% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Ipca Laboratories | Glaxosmithkline Pharmaceuticals |
|---|---|---|
| Price above 50-day average | ✗ | ✗ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✓ | ✓ |
| Positive 1-year return | ✓ | ✗ |
| Return on equity above 15% | ✓ | ✓ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✓ | ✗ |
| Score | 9/10 | 7/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Ipca Laboratories or Glaxosmithkline Pharmaceuticals?
Ipca Laboratories has a market cap of ₹49,263 Cr and Glaxosmithkline Pharmaceuticals has a market cap of ₹42,773 Cr as of 06 Nov 2026.
Which has a lower P/E, Ipca Laboratories or Glaxosmithkline Pharmaceuticals?
Ipca Laboratories has the lower P/E: Ipca Laboratories trades at 35.1 and Glaxosmithkline Pharmaceuticals at 83.0.
Which gave better returns in the last year, Ipca Laboratories or Glaxosmithkline Pharmaceuticals?
Ipca Laboratories did better: Ipca Laboratories returned +50.5% and Glaxosmithkline Pharmaceuticals returned -4.5% over one year.
Is Ipca Laboratories or Glaxosmithkline Pharmaceuticals a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Ipca Laboratories scores 9/10 and Glaxosmithkline Pharmaceuticals scores 7/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.